Belotero Revive 1x1ml

• Cross-linked sodium hyaluronate: 20 mg/ml, of non-animal origin, high molecular weight (2.7–3.3 m³/kg).
• Glycerol: 17.5 mg/ml. Acts as a humectant for the cutaneous tissue to preserve hydration.
• Cross-linker: BDDE, degree of modification < 5 %. Residual BDDE ≤ 2 ppm.
• Physiological phosphate buffer pH 7 q.s. to 1.0 ml, with sodium dihydrogen phosphate dihydrate 1.5 mg/ml and disodium phosphate 5.5 mg/ml.
• Without lidocaine.
• CPM® technology: gel with variable cross-linking densities. Revive is characterised by a lower gel density that allows the product to diffuse into the fine spaces of the pericellular tissue; its viscoelastic properties establish a condensed network within the extracellular matrix to improve skin turgor and hydration.

Revive is the only reference in the range that incorporates glycerol and the only one whose purpose is not to fill a fold or provide volume, but to improve skin hydration, elasticity and firmness.

Resorbable injectable implant intended to revitalise the skin of the face by rehydrating dry and very dry skin, improving elasticity and firmness and smoothing fine superficial wrinkles, reducing skin roughness.

• Instructions for Use indication: revitalisation of early-onset photodamaged facial skin on the cheeks, characterised by dehydration, loss of elasticity and firmness and the presence of fine superficial wrinkles.

Must not be injected into the glabellar or nasal region, into blood vessels, into skin with active inflammation or infection, or into areas previously treated with a permanent filler.

Documented duration: up to 9 months according to the manufacturer's clinical data.

• Injection plane: mid and deep dermis.
• Needles included: 2 × 30G ½".
• Technique recommended by the manufacturer: serial micropuncture — several injections of very small amounts distributed evenly, approximately 50 µl per point, with 20–30 points spaced 1–2 cm apart.
• Other accepted techniques: linear or serial threading, fanning and cross-hatching.
• Dosing guidance: up to 3 ml in the cheeks in a single session, or three sessions with a maximum of 2 ml per session separated by at least 4 weeks. The regimen may be repeated at the earliest after 6 months, with a maximum annual dose of 12 ml.
• Vascular risk: prior aspiration, low volumes and serial injections in high-risk areas, treating one side at a time and manual occlusion of the origin of the supratrochlear vessels. Blunt cannulas reduce the risk but do not eliminate it.
• Do not overcorrect. Gently massage the treated area if necessary.
• Aftercare: observation of up to 30 minutes after injection; avoid alcohol 24 h before and after; no make-up for at least 12 h; avoid sauna, peels, steam baths, prolonged sun exposure, UV and extreme temperatures for 2 weeks.

• Storage: between 2 °C and 25 °C. Protect from light. Do not freeze. Store in a dry place and avoid mechanical impact.
• Visually inspect the integrity of the packaging and of the sterile barrier system before use. Do not use after the expiry date.
• Single-use product. Do not resterilise or reuse.
• The pack contains: 1 pre-filled glass syringe of 1.0 ml, 2 sterile 30G ½" needles, traceability labels, implant card, instructions for use and patient information leaflet.

Contraindications: known hypersensitivity to any of the components, in particular to sodium hyaluronate, to glycerol or to BDDE; pregnancy and breastfeeding; under 18 years of age; general infection; active autoimmune disease.

Do not inject into blood vessels, into the glabellar or nasal region, into skin with active inflammation or infection, or into areas treated with a permanent dermal filler.

Warnings: rare but serious events associated with intravascular injection of facial fillers have been reported — vascular occlusion, visual impairment, blindness, cerebral ischaemia or haemorrhage, skin necrosis. Stop the injection immediately in the event of changes in vision, signs of stroke, skin blanching or unusual pain, and refer for urgent medical care. Sodium hyaluronate precipitates in the presence of quaternary ammonium salts (e.g. benzalkonium chloride).

Precautions: individual assessment in cases of a history of multiple severe allergies or anaphylactic shock; not recommended in cases of a history of streptococcal disease or a tendency to hypertrophic or keloid scarring; anticoagulants, antiplatelet agents and NSAIDs increase the risk of haematoma; do not combine with peeling, dermabrasion or laser before complete healing and, in any case, not before 2 weeks. The implant card must be presented to the radiologist before magnetic resonance imaging.

Always consult the instructions for use included in the pack before application.